Home » Newsletters » BioWorld Science

BioWorld Science

July 15, 2009

View Archived Issues

Enanta Pharmaceuticals claims new NS3/NS4A protease inhibitors for the treatment of HCV

MaxThera presents novel PPAT inhibitors for the treatment of bacterial infections

Novel PDE10A inhibitors in early development at BioTie Therapies as antipsychotics

Purdue Pharma discovers opioid receptor agonists and antagonists for the treatment of constipation

Novavax and Cadila launch joint venture in India

Merck & Co. and Portola sign worldwide license agreement for betrixaban

Spectrum submits response to FDA's complete response letter regarding sBLA for Zevalin

TRION reports new data on the mechanism of action of ertumaxomab

Discreet effect of rosiglitazone on vascular disease progression in prediabetic patients

Novel alpha7 nAChR agonist EVP-5141 improves cognitive ability in vivo

Vertex plans to sell rights to certain milestone payments related to telaprevir in Europe

AstraZeneca and MAP Pharmaceuticals terminate license agreement for unit dose budesonide

Addex achieves second preclinical milestone under PD collaboration with Merck & Co.

Sorafenib evaluated in different subtypes of recurrent or metastatic sarcoma

Sunitinib active in phase II non-GIST stromal tumor sarcomas trial

Cellceutix reports successful animal testing data for Kevetrin in lung cancer cell lines

Evotec enters fragment-based drug discovery agreement with Cubist

MediciNova proposes final protocol for phase II MN-221 trial in asthma

Can-Fite BioPharma receives approval to commence phase I/II trial for CF-102 in hepatitis C

Sunesis receives milestone payment from Biogen Idec for selection of Raf kinase inhibitor

PharmaMar releases statement regarding FDA oral session to discuss Yondelis

Hisamitsu to acquire Noven for USD 428 million in an all-cash tender offer

NovaMed signs agreements with Iroko and EUSA Pharma

PharmaSurgics completes phase I study of PXL-01 for postsurgical adhesion formation

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...